{"nctId":"NCT00117338","briefTitle":"A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)","startDateStruct":{"date":"2005-07"},"conditions":["Asthma"],"count":276,"armGroups":[{"label":"1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: placebo (unspecified)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: montelukast sodium"]}],"interventions":[{"name":"montelukast sodium","otherNames":["MK0476","SINGULAIR®"]},{"name":"Comparator: placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Children 6-14 years of age seeking treatment in emergency departments with acute asthma attacks\n\nExclusion Criteria:\n\n* Other respiratory conditions (including congenital lung abnormalities) or other acute illnesses that would complicate current treatment and response for asthma","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"14 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After Administration","description":"Improvement in FEV1 as the time-weighted average change from baseline over 60 minutes following the end of study drug administration. Time-weighted average of the changes from baseline obtained over the 60 minutes (at 60, 45, 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":null},{"groupId":"OG001","value":"0.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Modified Pulmonary Index [mPI] Score","description":"Change from baseline in modified pulmonary index \\[mPI\\] score assessed 60 minutes following the end of study drug administration. mPI questionnaire scores each component on a scale of 0 to 3 (low to high) with a total possible score of 12.\n\nThe components are respiratory rate, wheezing, prolongation of expiration (Inspiratory:Expiratory ratio), and accessory muscle use.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.95","spread":null},{"groupId":"OG001","value":"-2.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Failure (Hospitalization or Time to Decision to Discharge > 2 Hours)","description":"Treatment Failure is defined as a.) patients who required hospitalization, or b.) patients for whom a decision to discharge home has not been reached by 2 hours following the end of study drug administration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average Change in FEV1 Over 45 Minutes Following the End of Study Drug Administration","description":"Improvement in FEV1 as time-weighted average change from baseline over 45 minutes following the end of study drug administration: Time-weighted average of the changes from baseline obtained over the 45 minutes (at 45, 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Time-Weighted Average Change in FEV1 Over 30 Minutes Following the End of Study Drug Administration","description":"Improvement in FEV1 as the time-weighted average change from baseline over 30 minutes following the end of study drug administration. Time-weighted average of the changes from baseline obtained over the 30 minutes (at 30 and 15) with the time interval between any measurement and the measurement prior to it used as the weighting factor.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in FEV1 After 15 Minutes Following the End of Study Drug Administration","description":"Improvement in FEV1 as the time-weighted average change from baseline over the first 15 minutes following the end of study drug administration. Change = 15 minutes value minus Baseline value","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":null},{"groupId":"OG001","value":"0.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Dose of β-agonist Administered Per Patient Over a Period of 2 Hours Following the End of Study Drug Administration","description":"Median total dose of β-agonist administered per patient over a period of 2 hours following the end of study drug administration.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2},"commonTop":["Any Respiratory, Thoracic And Mediastinal Disorders","Any Gastrointestinal Disorders","Asthma","Any Infections And Infestations","Any Nervous System Disorders"]}}}